Orchestra BioMed (OBIO) Stock Price, News & Analysis

Company Overview

Orchestra BioMed Holdings, Inc. is a clinical-stage healthcare company developing products for the treatment of cardiovascular and other serious medical conditions. The company uses a partnership-oriented business model, working with medical device and healthcare companies to advance novel therapies toward commercialization.

Orchestra BioMed’s leading program is BackBeat Cardiac Neuromodulation Therapy, an investigational device-based treatment designed to provide sustained reductions in blood pressure for patients with hypertension. The therapy is being developed in collaboration with Medtronic and combines an implantable pulse generator with proprietary neuromodulation technology.

The company is also developing Virtue Sirolimus AngioInfusion™ Balloon technology, an investigational balloon-based system intended to deliver a therapeutic drug to blood vessels during interventional procedures. Orchestra BioMed has collaborated with Terumo Corporation on development of this program, which is aimed at addressing vascular disease and reducing the risk of restenosis.

Orchestra BioMed was formed through a business combination with ARYA Sciences Acquisition Corp IV and began trading on the Nasdaq under the symbol OBIO in 2023. David Hochman serves as the company’s chairman and chief executive officer. Its development activities are focused on the United States and international markets through clinical programs and strategic industry partnerships.

Key Stats

• Today's Range: $6.00 to $6.29
• 50-Day Range: $3.63 to $6.25
• 52-Week Range: $2.42 to $6.48
• Volume: 95,958 shs
• Average Volume: 274,465 shs
• Market Capitalization: $371.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.17
• Consensus Rating: Moderate Buy

Orchestra BioMed Stock Analysis - MarketRank™

Orchestra BioMed scored higher than 78% of companies evaluated by MarketBeat, and ranked 158th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Orchestra BioMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Orchestra BioMed has a consensus price target of $13.17, representing about 112.1% upside from its current price of $6.21.

Amount of Analyst Coverage

Orchestra BioMed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Orchestra BioMed are expected to grow in the coming year, from ($1.53) to ($1.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Orchestra BioMed is -7.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orchestra BioMed is -7.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Orchestra BioMed has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.27% of the float of Orchestra BioMed has been sold short.

Short Interest Ratio / Days to Cover

Orchestra BioMed has a short interest ratio ("days to cover") of 6.57.

Change versus previous month

Short interest in Orchestra BioMed has recently decreased by 3.58%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orchestra BioMed does not currently pay a dividend.

Dividend Growth

Orchestra BioMed does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Orchestra BioMed has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Orchestra BioMed this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Orchestra BioMed in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Orchestra BioMed insiders have sold 131.30% more of their company's stock than they have bought. Specifically, they have bought $58,560.00 in company stock and sold $135,450.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Orchestra BioMed is held by insiders.

Percentage Held by Institutions

53.20% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:OBIO
• CIK: 1814114
• Web: orchestrabiomed.com
• Phone: (646) 343-9298
• Fax: N/A
• Employees: 4
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Orchestra BioMed: $13.17
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +111.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.70 million
• Net Margins: -184.60%
• Pretax Margin: -184.60%
• Return on Equity: -149.61%
• Return on Assets: -54.15%

Debt

• Debt-to-Equity Ratio: 1.80
• Current Ratio: 8.26
• Quick Ratio: 8.24

Sales & Book Value

• Annual Sales: $31.98 million
• Price / Sales: 11.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.95 per share
• Price / Book: 6.56

Miscellaneous

• Outstanding Shares: 60,105,000
• Free Float: 55,597,000
• Market Cap: $374.45 million
• Optionable: Not Optionable
• Beta: 0.54